The tegenero incident and the duff report conclusions: A series of unfortunate events or an avoidable event?

Toxicologic Pathology

Volumn 37, Issue 3, 2009, Pages 372-383

  Horvath, Christopher J ^a   Milton, Mark N ^b  

^a Taligen Therapeutics   (United States)

^b Tempo Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; TGN 1412; VISILIZUMAB; CD28 ANTIGEN; DRUG; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN1412;

CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; HEADACHE; HUMAN; HYPOTENSION; INCIDENCE; LOW DRUG DOSE; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VASODILATATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; HEALTH CARE PLANNING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PHARMACOKINETICS; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL; STANDARD;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; CLINICAL TRIALS, PHASE I AS TOPIC; HEALTH PLANNING GUIDELINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 67049107952     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309332986     Document Type: Review

References (64)

1. Alegre, ML, AM Collins, VL Pulito, RA Brosius, WC Olson, RA Zivin, R Knowles, JR Thistlethwaite, LK Jolliffe, and JA Bluestone (1992). Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol, 148, 3461-68.
2. Alegre, ML, M Depierreux, S Florquin, T Najdovski, P Vandenabeele, D Abramowicz, O Leo, M Deschodt-Lanckman, and M Goldman (1990). Acute toxicity of anti-CD3 monoclonal antibody in mice: A model for OKT3 first dose reactions. Transplant Proc, 22, 1920-21.
3. Association of the British Pharmaceutical Industry and BioIndustry Association (APBI/BIA) (1977). Guidelines for preclinical testing on new medicinal products. Parts 1 and 2. London.
4. (1959). Appraisal of the safety of chemicals in food, drugs and cosmetics.
5. Beyersdorf, N, T Hanke, T Kerkau, and T Hünig (2006). CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev, 5, 40-45.
6. BioSafe General Membership Meeting (2008). Cytokine release assays: Current approaches and considerations. In Cytokine release assays: Current approaches and considerations. Cambridge, MA.
7. Chatenoud, L, C Ferran, and JF Bach (1990). In vivo use of OKT3: Main issues for the monitoring of treated patients. Transplant Proc, 22, 2605-8.
8. Cole, MS, KE Stellrecht, JD Shi, M Homola, DH Hsu, C Anasetti, M Vasquez, and JY Tso (1999). HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation, 68, 563-71.
9. DeGeorge, JJ, CH Ahn, PA Andrews, ME Brower, DW Giorgio, MA Goheer, DY Lee-Ham, WD McGuinn, W Schmidt, CJ Sun, and SC Tripathi (1997). Regulatory considerations for pre-clinical development of anticancer drugs. Cancer Chemother Pharmacol, 41, 173-85.
10. Early Stage Clinical Trial Taskforce (2007). Early Stage Clinical Trial Taskforce-Joint ABPI/BIA report. Association of the British Pharmaceutical Industry and BioIndustry Association.
11. (2004). Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599/02/Rev 1.
12. (2007). EMEA guidance for companies requesting scientific advice or protocol assistance. EMEA-H-4260-01-Rev. 4.
13. Expert Group on Phase One Clinical Trials (chairman: Professor Gordon W. Duff) (2006). Expert group on phase one clinical trials: Final report. TSO (The Stationary Office).
14. FDA CDER Immunotoxicology Subcommittee Meeting (2008). Cytokine release: What does it mean to you?. In Cytokine release: What does it mean to you?. Rockville, MD: FDA White Oak Campus.
15. FDA Science Board, Subcommittee on Science and Technology (2007). FDA science and mission at risk. Washington, DC.
16. Gambrill, S (November 8, 2006). Can EU regulators keep up with innovation? Clinical Trials Today. http://www.clinicaltrialstoday.com/2006/11/ can-eu-regulato.html. (accessed November 4, 2008).
17. Gaston, RS, MH Deierhoi, T Patterson, E Prasthofer, BA Julian, WH Barber, DA Laskow, AG Diethelm, and JJ Curtis (1991). OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int, 39 (1). 141-48.
18. Gibb, F (2008). Victim Ryan Wilson in "elephant man" drug trial to get £2m. In The Times. London.
19. Greaves, P, A Williams, and M Eve (2004). First dose of potential new medicines to humans: How animals help. Nat Rev Drug Discov, 3, 226-36.
20. Hale, G, DM Swirsky, FG Hayhoe, and H Waldmann (1983). Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med, 1, 321-34.
21. Hsu, DH, JD Shi, M Homola, TJ Rowell, J Moran, D Levitt, B Druilhet, J Chinn, C Bullock, and C Klingbeil (1999). A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation, 68, 545-54.
22. Huang, C, M Zheng, Z Yang, AD Rodrigues, and P Marathe (2008). Projection of exposure and efficacious dose prior to first-in-human studies: How successful have we been? Pharm Res, 25, 713-26.
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (June 10, 1996). ICH harmonised tripartite guideline. Good clinical practice: Consolidated guideline. E6(R1).. http://www.ich.org/LOB/media/MEDIA482.pdf. (accessed March 6, 2008).
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1998). ICH harmonised tripartite guideline Statistical principles for clinical trials. E9. http://www.ich.org/LOB/media/MEDIA485.pdf. (accessed March 28, 2008).
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (November 9, 2000). ICH harmonised tripartite guideline. Maintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. M3(R1). http://www.ich.org/LOB/media/MEDIA506.pdf. (accessed March 4, 2008).
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (July 15, 2008a). ICH harmonised tripartite guideline. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. M3(R2). Step 2. http://www.ich.org/LOB/media/MEDIA4744.pdf. (accessed August 21, 2008).
27. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2008b). ICH Steering Committee meeting. Monitoring and Protecting the Global Public Health, May 31-June 5, Portland, Oregon, USA. http://www.ich.org/cache/compo/276-254-1.html. (accessed August 21, 2008).
28. Klingbeil, C, and DH Hsu (1999). Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol, 27, 1-3.
29. Legrand, N, T Cupedo, AU van Lent, MJ Ebeli, K Weijer, T Hanke, and H Spits (2006). Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(/)gammac(/) mice. Blood, 108, 238-45.
30. Liedert, B, S Bassus, CK Schneider, U Kalinke, and J Lower (2007). Safety of Phase I clinical trials with monoclonal antibodies in Germany - The regulatory requirements viewed in the aftermath of the TGN1412 disaster. Intl J Clin Pharm Thera, 45, 1-9.
31. Lin, CH, and T Hunig (2003). Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol, 33, 626-38.
32. Lowe, PJ (2007). On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica, 37, 1331-54.
33. Lühder, F, Y Huang, KM Dennehy, C Guntermann, I Müller, E Winkler, T Kerkau, S Ikemizu, SJ Davis, T Hanke, and T Hünig (2003). Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med, 197, 955-66.
34. Mahmood, I (2005). The correction factors do help in improving the prediction of human clearance from animal data. J Pharm Sci, 94, 940-45.
35. Medicines and Healthcare Products Regulatory Agency (MHRA) (April 5, 2006a). Clinical trial suspension: Latest findings. http://www.mhra.gov.uk/ NewsCentre/Pressreleases/CON2023515. (accessed March 26, 2008).
36. Medicines and Healthcare Products Regulatory Agency (MHRA) (2006b). Investigations into adverse incidents during clinical trials of TGN1412 (interim report). London: MHRA.
37. Milton, MN, and CJ Horvath (2009). The EMEA guideline on first-inhuman clinical trials and its impact on pharmaceutical development. Toxicol Pathol, 37, 363-371.
38. Müller, N, J van den Brandt, F Odoardi, D Tischner, J Herath, A Flügel, and HM Reichardt (2008). A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest, 118, 1405-16.
39. Nagilla, R, and KW Ward (2004). A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci, 93, 2522-34.
40. Nagilla, R, and KW Ward (2005a). Correspondence. J Pharm Sci, 94, 946-47.
41. Nagilla, R, and KW Ward (2005b). Erratum: A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci, 94, 231-32.
42. Nguyen, DH, N Hurtado-Ziola, P Gagneux, and A Varki (2006). Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA, 103, 7765-70.
43. Norman, DJ, F Vincenti, AM de Mattos, JM Barry, DJ Levitt, NI Wedel, M Maia, and SE Light (2000). Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation, 70, 1707-12.
44. Rao, PE, G Olini, J Kille, E Muchmore, MA Talle, G Brake, and SA Rudnick (1991). OKT3E, an anti-CD3 antibody that does not elicit side effects or antiidiotype responses in chimpanzees. Transplantation, 52, 691-97.
45. Rowland, M (2007). Commentary on ACCP position statement on the use of microdosing in the drug development process. J Clin Pharmacol, 47, 1595-96.
46. Royal Statistical Society (RSS) (2007). Report of the working party on statistical issues in first-in-man studies. London: RSS.
47. Schwieterman, W (2006). Regulating biopharmaceuticals under CDER versus CBER: An insider's perspective. Drug Discov Today, 11, 945-51.
48. Senn, S, D Amin, R Bailey, S Bird, B Bogacka, P Colman, A Garett, A Grieve, and P Lachman (2007). Statistical issues in first-in-man studies. J Royal Stat Soc A, 170, 517-79.
49. Sims, J (2007). Calculation of the minimum anticipated biological effect level (MABEL) and 1st dose in humans, in EMEA Workshop on the Guideline for First-in-Man Clinical Trials for potential high-risk medicinal products. ABPI/BIA Early Stage Clinical Trials Task Force.
50. Smirnova, I, A Poltorak, EK Chan, C McBride, and B Beutler (2000). Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol, 1, RESEARCH002.
51. St Clair, EW (2008). The calm after the cytokine storm: Lessons from the TGN1412 trial. J Clin Invest, 118, 1344-47.
52. Stebbings, R (2007). "Cytokine storm" in the Phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve pre-clinical testing of immunotherapeutics". J Immunol, 179, 3325-31.
53. Suntharalingam, G, MR Perry, S Ward, SJ Brett, A Castello-Cortes, MD Brunner, and N Panoskaltsis (2006). Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med, 355, 1018-28.
54. Tabrizi, MA, and LK Roskos (2007). Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today, 12 (13-14). 540-47.
55. Tacke, M, G Hanke, T Hanke, and T Hünig (1997). CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol, 27, 239-47.
56. U.S. Food and Drug Administration (FDA), U.S. Food and Drug Administration (FDA) (2005a). Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Washington, DC.
57. U.S. Food and Drug Administration (FDA) (2005b). Guidance for industry, investigators, and reviewers: Exploratory IND studies (Draft). Washington, DC.
58. U.S. Food and Drug Administration (FDA) (2006). Guidance for industry, investigators and reviewers: Exploratory IND studies. Washington, DC.
59. Van Wauwe, JP, JR De Mey, and JG Goossens (1980). OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol, 124, 2708-13.
60. Waibler, Z, LY Sender, C Merten, R Hartig, S Kliche, M Gunzer, P Reichardt, U Kalinke, and B Schraven (2008). Signaling signatures and functional properties of anti-human cd28 superagonistic antibodies. PLoS ONE, 3, e1708.
61. Ward, KW, and BR Smith (2004a). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos, 32, 603-11.
62. Ward, KW, and BR Smith (2004b). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos, 32, 612-19.
63. Wing, MG, T Moreau, J Greenwood, RM Smith, G Hale, J Isaacs, H Waldmann, PJ Lachmann, and A Compston (1996). Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest, 98, 2819-26.
64. Winkler, U, M Jensen, O Manzke, H Schulz, V Diehl, and A Engert (1999). Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 94, 2217-24.